PE20221592A1 - Compuestos heterociclicos de heteroarilo y usos de los mismos - Google Patents
Compuestos heterociclicos de heteroarilo y usos de los mismosInfo
- Publication number
- PE20221592A1 PE20221592A1 PE2022001746A PE2022001746A PE20221592A1 PE 20221592 A1 PE20221592 A1 PE 20221592A1 PE 2022001746 A PE2022001746 A PE 2022001746A PE 2022001746 A PE2022001746 A PE 2022001746A PE 20221592 A1 PE20221592 A1 PE 20221592A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- dihydro
- pyrazin
- halogen
- bispyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- UCXWCHYDUONYDF-UHFFFAOYSA-N 10-[4-[5-[(5-acetyl-6,7-dihydro-4H-pyrazolo[1,5-a]pyrazin-2-yl)amino]-1-methyl-6-oxopyridin-3-yl]-3-(hydroxymethyl)pyridin-2-yl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7,11-trien-9-one Chemical compound O=C(N1CCN2C(C1)=CC(NC1=CC(C3=CC=NC(=C3CO)N3C(=O)C=4N(C=5CC(C)(C)CC=5C=4)C=C3)=CN(C1=O)C)=N2)C UCXWCHYDUONYDF-UHFFFAOYSA-N 0.000 abstract 1
- FQFSMIURXHIFAJ-XZOQPEGZSA-N 10-[4-[5-[[5-[(2S,5R)-2,5-dimethyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-1-methyl-6-oxopyridin-3-yl]-3-(hydroxymethyl)pyridin-2-yl]-1,10-diazatricyclo[6.4.0.02,6]dodeca-2(6),7,11-trien-9-one Chemical compound C[C@H](CN([C@@H](C)C1)C2=CC=C(NC3=CC(C4=CC=NC(N(C=CN5C6=CC7=C5CCC7)C6=O)=C4CO)=CN(C)C3=O)N=C2)N1C1COC1 FQFSMIURXHIFAJ-XZOQPEGZSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010066476 Haematological malignancy Diseases 0.000 abstract 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta referido a un compuesto heterociclico de Formula I, en donde: R1 y R2 son H, deuterio, halogeno, alquilo, alquinilo, entre otros; X1 y X2 son CH o N; X3 y X4 son C o N; Y1 e Y2 son CR10 o N; R3 es H, deuterio, halogeno, haloalquilo; R4 es H, halogeno, CN, alquilo, alquinilo, alquil-OH, entre otros; R5 es H, alquilo, CO-alquilo, CO-cicloalquilo, entre otros; y, Cy es una de las formulas que se indica a continuacion. Entre los compuestos preferidos tenemos los siguientes: 2-(5-((5-((2S,5R)-2,5-dimetil-4-(oxetan-3-il)piperazin-1-il)piridin-2-il)amino)-3'-(hidroximetil)-1- metil-6-oxo-1,6-dihidro-[3,4'-bispiridin]-2'-il)-7,8-dihidro-2H-ciclopenta[4,5]pirrolo[1,2- a]pirazin-1(6H)-ona; 2-(5-((5-acetil-4,5,6,7-tetrahidropirazolo[1,5-a]pirazin-2-il)amino)-3'-(hidroximetil)-1-metil-6- oxo-1,6-dihidro-[3,4'-bispiridin]-2'-il)-7,7-dimetil-7,8-dihidro-2H-ciclopenta[4,5]pirrolo[1,2- a]pirazin-1(6H)-ona; entre otros. Estos compuestos son inhibidores de la actividad de BTK in vivo o in vitro, y se emplean para tratar o prevenir el cancer, una enfermedad inflamatoria o una enfermedad autoinmune, en donde el cancer es preferiblemente tumor solido o enfermedad hematologica maligna, que incluye linfoma, leucemia y mieloma.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010104062 | 2020-02-20 | ||
| CN202110169142 | 2021-02-07 | ||
| PCT/CN2021/076869 WO2021164735A1 (en) | 2020-02-20 | 2021-02-19 | Heteroaryl heterocyclic compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221592A1 true PE20221592A1 (es) | 2022-10-10 |
Family
ID=77390445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001746A PE20221592A1 (es) | 2020-02-20 | 2021-02-19 | Compuestos heterociclicos de heteroarilo y usos de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11478474B2 (es) |
| EP (1) | EP4107154A4 (es) |
| JP (1) | JP2023515099A (es) |
| KR (1) | KR20220158712A (es) |
| CN (1) | CN115151535A (es) |
| AU (1) | AU2021222197A1 (es) |
| BR (1) | BR112022016432A2 (es) |
| CA (1) | CA3171012A1 (es) |
| CL (1) | CL2022002255A1 (es) |
| IL (1) | IL295589A (es) |
| MX (1) | MX2022010219A (es) |
| PE (1) | PE20221592A1 (es) |
| TW (1) | TW202140488A (es) |
| WO (1) | WO2021164735A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021164735A1 (en) | 2020-02-20 | 2021-08-26 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
| CA3195525A1 (en) * | 2020-09-21 | 2022-03-24 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
| WO2023143491A1 (zh) * | 2022-01-28 | 2023-08-03 | 和记黄埔医药（上海）有限公司 | 7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2726460C (en) | 2008-07-15 | 2017-02-21 | F. Hoffmann-La Roche Ag | Novel phenyl-imidazopyridines and pyridazines |
| NZ604004A (en) | 2010-05-07 | 2014-06-27 | Gilead Connecticut Inc | Pyridone and aza-pyridone compounds and methods of use |
| EA027561B1 (ru) | 2011-11-03 | 2017-08-31 | Ф.Хоффманн-Ля Рош Аг | Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона |
| BR112014010460A2 (pt) | 2011-11-03 | 2017-04-18 | Hoffmann La Roche | composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica |
| KR20140096100A (ko) * | 2011-11-03 | 2014-08-04 | 에프. 호프만-라 로슈 아게 | 이환 피페라진 화합물 |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| KR101673728B1 (ko) | 2011-12-09 | 2016-11-07 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| CN110698481B (zh) * | 2013-07-03 | 2023-02-28 | 豪夫迈·罗氏有限公司 | 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物 |
| CA2929918C (en) * | 2013-12-05 | 2018-01-23 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| EP3201186B1 (en) | 2014-10-02 | 2019-02-27 | F. Hoffmann-La Roche AG | Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk) |
| AR102177A1 (es) | 2014-10-06 | 2017-02-08 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos |
| CA3034239A1 (en) | 2016-08-16 | 2018-02-22 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof |
| TWI766176B (zh) | 2016-12-15 | 2022-06-01 | 瑞士商赫孚孟拉羅股份公司 | 製備btk抑制劑之方法 |
| UY37559A (es) * | 2017-01-06 | 2018-05-31 | Pharmacyclics Llc | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton |
| US11100492B2 (en) | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
| CN110256446B (zh) * | 2018-08-01 | 2021-12-14 | 上海海雁医药科技有限公司 | 苯并杂环取代的环戊二烯并[4,5]吡咯并吡嗪-1-酮衍生物及其应用 |
| WO2021164735A1 (en) * | 2020-02-20 | 2021-08-26 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
-
2021
- 2021-02-19 WO PCT/CN2021/076869 patent/WO2021164735A1/en active Application Filing
- 2021-02-19 MX MX2022010219A patent/MX2022010219A/es unknown
- 2021-02-19 CA CA3171012A patent/CA3171012A1/en active Pending
- 2021-02-19 BR BR112022016432A patent/BR112022016432A2/pt unknown
- 2021-02-19 PE PE2022001746A patent/PE20221592A1/es unknown
- 2021-02-19 JP JP2022550035A patent/JP2023515099A/ja active Pending
- 2021-02-19 EP EP21756469.9A patent/EP4107154A4/en active Pending
- 2021-02-19 AU AU2021222197A patent/AU2021222197A1/en active Pending
- 2021-02-19 CN CN202180015458.2A patent/CN115151535A/zh active Pending
- 2021-02-19 KR KR1020227032457A patent/KR20220158712A/ko unknown
- 2021-02-19 IL IL295589A patent/IL295589A/en unknown
- 2021-02-19 TW TW110105765A patent/TW202140488A/zh unknown
- 2021-10-20 US US17/506,220 patent/US11478474B2/en active Active
-
2022
- 2022-08-18 CL CL2022002255A patent/CL2022002255A1/es unknown
- 2022-08-31 US US17/823,889 patent/US12070457B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202140488A (zh) | 2021-11-01 |
| IL295589A (en) | 2022-10-01 |
| US20220125785A1 (en) | 2022-04-28 |
| MX2022010219A (es) | 2022-09-19 |
| WO2021164735A1 (en) | 2021-08-26 |
| CL2022002255A1 (es) | 2023-03-10 |
| US12070457B2 (en) | 2024-08-27 |
| US11478474B2 (en) | 2022-10-25 |
| EP4107154A1 (en) | 2022-12-28 |
| KR20220158712A (ko) | 2022-12-01 |
| EP4107154A4 (en) | 2024-02-28 |
| CN115151535A (zh) | 2022-10-04 |
| US20230043030A1 (en) | 2023-02-09 |
| BR112022016432A2 (pt) | 2022-11-16 |
| JP2023515099A (ja) | 2023-04-12 |
| CA3171012A1 (en) | 2021-08-26 |
| AU2021222197A1 (en) | 2022-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20221592A1 (es) | Compuestos heterociclicos de heteroarilo y usos de los mismos | |
| KR102007135B1 (ko) | 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물 | |
| ES2608940T3 (es) | Derivado de bicicloanilina | |
| AU2019243289B2 (en) | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer | |
| ES2926124T3 (es) | Inhibidor de FGFR4, método de preparación del mismo y uso farmacéutico del mismo | |
| TW202140024A (zh) | Shp2抑制劑嘧啶酮與新穎癌症醫藥併用於癌症之抗腫瘤活性之增強 | |
| WO2022232331A1 (en) | Heterocyclic compounds and methods of use | |
| KR20230167071A (ko) | 유비퀴틴-특이적 프로테아제 1 (usp1)의 억제 | |
| PT2016080E (pt) | Derivados da di-hidropirazolopirimidinona | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| RU2017137514A (ru) | Имидазопиразиноны в качестве ингибиторов pde1 | |
| PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
| CN113861188B (zh) | 吡唑并[3,4-b]吡啶类衍生物及其制备方法和作为HPK1抑制剂的应用 | |
| RU2015100213A (ru) | Замещенные соединения пиридин азолопиримидин-5-(6н)-она | |
| JP2024532733A (ja) | 複素環式化合物及び使用方法 | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| JP2019514878A5 (es) | ||
| PE20060600A1 (es) | Derivados de aminopiridina como inhibidores selectivos de la aurora a quinasa | |
| JP2015526394A5 (es) | ||
| JP2024532735A (ja) | 複素環式化合物及び使用方法 | |
| PE20050074A1 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante | |
| RU2008133306A (ru) | Соединенные мостиковой связью n-циклические сульфонамидо-ингибиторы гамма-секретазы | |
| RU2019108717A (ru) | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов | |
| JP2018514552A5 (es) | ||
| AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa |